Page 311 - Drug Class Review
P. 311
Drug Effectiveness Review Project
Groups similar at baseline: Yes
Alzheimer classification: NR
galantamine placebo 75.2 75.0 46 48 0% 0.5% 99.8% 99.5% 0.2% 0% 24.1 22.3 20.2 20.7 Primary Outcome Measures: ADAS-Cog 11; CIBIC-plus (only primary outcome measures reported in the subgroup analysis of patients with AD & CVD) Secondary Outcome Measures: ADAS-Cog 13; NPI; DAD Timing of assessments: ADAS-Cog 11 performed at screening, baseline, 6 weeks, and months 3 and 6; CIBIC-plus, NPI, and DAD performed at baseline, and months 3 and 6 Subgroup analysis for AD-patients with CVD (ADAS-Cog & CIBIC-plus only): Health Outcome M
• • •
Final Report Update 1 Authors: Erkinjuntti et al. Year: 2002 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Black • White • Asian • Other germane population qualities: ADAS-Cog score • MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
